Rare bone disease with expertise in Fibrodysplasia Ossificans Progressiva and hypophosphatasia. Metabolic bone and calcium disorders including osteoporosis, Paget's disease, hypo- and hyper-parathyroidism as well as bone diseases related to transplant, medications (example aromatase inhibitors and glucocorticoids) and iron overload.
Clinical research in Fibrodysplasia Ossificans Progressiva and hypophosphatasia.
Evaluation of osteoporosis and the effects of treatment/diseases on "bone quality" using high resolution imaging of bone (uMRI).
Selected Publications
Vincent A. Verheij, Robert J. Diecidue, Esmée Botman, Joseph D. Harrington, Nobuhiko Haga, Alberto Hidalgo-Bravo, Patricia L. R. Delai, Vrisha Madhuri, Mona Al Mukaddam, Keqin Zhang, Tae-Joon Cho, Rolf Morhart, Richard Keen, Carmen L. De Cunto, Clive S. Friedman, Zvi Grunwald, Michael Zasloff, J. Coen Netelenbos, Edward Hsiao, Frederick S. Kaplan, Robert J. Pignolo, Christiaan Scott and Elisabeth Marelise W. Eekhoff: Palovarotene in fibrodysplasia ossificans progressiva: review and perspective
Expert Opinion on Pharmacotherapy January 2025 Notes: https://doi.org/10.1080/14656566.2025.2452938.
Edward C. Hsia, Robert J. Pignolo, Mona Al Mukaddam, Geneviève Baujat, Staffan K. Berglund, Angela M. Cheung, Carmen De Cunto, Patricia Delai, Peter Kannu, Richard Keen, Edna E. Mancilla, Fei Shih, Andrew Strahs and Frederick S. Kaplan: The Impact of Palovarotene Treatment on Heterotopic Ossification in Patients with Fibrodysplasia Ossificans Progressiva With and Without Flare-Ups: Data from the Phase III MOVE Trial and Natural History Study. Poster presentation ASBMR annual meeting, Toronto, CA Sept 2024 Notes: Poster.
Tarun Mattikalli, Rashad Madi, Steven Graham, Julio Ojea Quintana, Hannah Rosenblatt, Bruce J. Kneeland, Amna Nabeel Khan, Benjamin T. Newman, Elena Taratuta, Mona Al Mukaddam, Chamith S. Rajapakse: Using Machine Learning Algorithms for High-Risk Patient Identification in Atypical Femoral Fractures. Poster presentation ASBMR annual meeting, Toronto, CA Sept 2024 Notes: Poster.
Keen R, Dahir KM, McGinniss J, Sanchez RJ, Mellis S, Economides AN, Di Rocco M, Orcel P, Roux C, Tabarkiewicz J, Bachiller-Corral J, Cheung AM, Al Mukaddam M, Mohammadi K, Gu J, Srinivasan D, Trotter DG, Eekhoff EMW, Kaplan FS, Pignolo RJ.: Characterization of flare-ups and impact of Garetosmab in adults with Fibrodysplasia Ossificans Progressiva: a post hoc analysis of the randomized, double-blind, placebo-controlled LUMINA-1 trial. J Bone Miner Res 26(39): 1486-1492, Aug 2024 Notes: doi: 10.1093/jbmr/zjae140.
Patricia Delai, Mona Al Mukaddam, Geneviève Baujat, Carmen De Cunto, Edward C. Hsiao, Richard Keen, Kim Croskery, Jean-Luc Delhay, Christelle Pommie, Robert J. Pignolo: Incidence and management of skin adverse events in patients receiving palovarotene for the treatment of fibrodysplasia ossificans progressiva. Poster Presentation at ICCBH Salzburg, Austria June 2024.
Richard Keen, Robert J. Pignolo, Mona Al Mukaddam, Geneviève Baujat, Angela M. Cheung, Carmen De Cunto, Edward C. Hsiao, Jean-Luc Delhay, Fei Shih, Andrew Strahs, Frederick S. Kaplan: Assessments of bone mineralisation, strength and fracture of the lumbar spine in patients with fibrodysplasia ossificans progressiva treated with palovarotene: Data from the phase III MOVE trial and a phase II open-label extension
Poster Presentation at ICCBH Salzburg, Austria June 2024.
Javier Ocampo Mascaro, Richie Tran, Staci Kallish, Jessica Berman, Mona Al Mukaddam: Clinical Features Of Adult Hypophosphatasia And Correlation Between Laboratory Findings And Patient’s Symptomatology: A Retrospective Review At The Penn Bone Center. Poster Session Endocrine Society Annual Meeting June 2024.
Javier Ocampo Mascaro, Pamela Wax, Mona Al Mukaddam: Adult-Onset Hypophosphatasia Presenting as Low Alkaline Phosphatase Level Following Denosumab Use for Osteoporosis.
Poster Endocrine Society Annual Meeting June 2024.
Deborah Wenkert, Frederick S. Kaplan, Robert J. Pignolo, Edward C. Hsiao, Mona M Al Mukaddam, Eric Soliman, Victoria Smith, Pankaj Bhargava: ANDECAL, A Phase 2/3 study to determine the efficacy of the MMP9-inhibitor Andecaliximab to block new heterotopic ossification in FOP: Methodology for Part 1 of the Study
Poster Presentation at ICCBH Salzburg, Austria June 2024.
Edna E. Mancilla, Geneviève Baujat, Mona Al Mukaddam, Javier Bachiller-Corral, Staffan K. Berglund, Carmen De Cunto, Patricia Delai, Richard Keen, Riccardo Papa, Robert J. Pignolo, Sally Lanar, Alexia Marrel, Alexander Artyomenko, Kim Croskery, Christelle Pommie, Edward C. Hsiao: The impact of palovarotene on patients with fibrodysplasia ossificans progressiva: Results from participant interviews in the phase III PIVOINE trial.
Oral Presentation at ICCBH Salzburg, Austria June 2024.
back to top
Last updated: 03/19/2025
The Trustees of the University of Pennsylvania